中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 10
Oct.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(10): 2019-2026

Clinical features and prognosis of hepatocellular carcinoma： A single-center study of 850 cases

DOI: 10.12449/JCH241015
  • 1.

    Institute of Liver Diseases，Hubei Key Laboratory of Theoretical and Applied Research of Liver and Kidney in Traditional Chinese Medicine，Hubei Provincial Hospital of Traditional Chinese Medicine，Wuhan 430061，China

  • 2.

    The Affiliated Hospital of Hubei University of Chinese Medicine，Wuhan 430061，China

  • 3.

    Hubei Academy of Chinese Medicine，Wuhan 430074，China

  • 4.

    College of Traditional Chinese Medicine，Hubei University of Chinese Medicine，Wuhan 430065，China

Research funding:

Hubei Provincial Major R & D Program Projects (2023BCB126);

Public Health Leading Talents Training Program of Hubei Province (E weitong ［2021］ No.73)

More Information
  • Corresponding author: TAO Junxiu， 2547467429@qq.com （ORCID： 0000-0003-2172-8925）
  • Received Date: 2024-02-18
  • Accepted Date: 2024-04-02
  • Published Date: 2024-10-25
    Abstract
  •   Objective  To investigate the clinical features and prognosis of hepatocellular carcinoma （HCC）.  Methods  Medical records were collected from 850 HCC patients who were admitted to Hubei Provincial Hospital of Traditional Chinese Medicine from December 2014 to May 2022， and their clinical and prognostic features were analyzed. The chi-square test were used for comparison of categorical data between groups； the Kaplan-Meier method was used to calculate survival time and survival rate， and the log-rank test was used for comparison of survival time based on baseline features.  Results  Among the 850 HCC patients， male patients accounted for 82.6%， and the median age at initial diagnosis was 58.0 （49.0， 66.0） years， with the highest proportion of patients aged 50 ‍—‍ 69 years （59.8%）. The patients with HBV infection accounted for the highest proportion of 77.4%； at initial diagnosis， 49.2% of the patients had portal vein tumor thrombus， and 20.2% of the patients had extrahepatic metastasis， among which pulmonary metastasis accounted for the highest proportion of 44.2% （76/172）. The patients with Barcelona Clinic Liver Cancer （BCLC） stage A （0）， B， C， and D HCC accounted for 20.4%， 22.5%， 41.5%， and 15.6%， respectively. There was a significant difference in the distribution of BCLC stages between different groups based on sex （χ2=16.631， P=0.001）， age （χ2=24.261， P=0.019）， place of residence （χ2=39.776， P<0.001）， presence or absence of viral hepatitis （χ2=8.338， P=0.040）， and presence or absence of regular antiviral therapy before initial diagnosis （χ2=26.140， P<0.001）. Follow-up was performed for 489 patients till death， with a median survival time of 19.99 months （95% confidence interval ［CI］： 14.86 ‍—‍ 25.12）， and the 1-， 3-， 5-， and 10-year cumulative survival rates were 60.7%， 39.9%， 29.4%， and 22.7%， respectively. There was a significant difference in survival time between different groups based on age （χ2=13.452， P=0.009）， history of viral hepatitis （χ2=6.123， P=0.013）， regular antiviral therapy before initial diagnosis （χ2=15.505， P<0.001）， comorbidity with type 2 diabetes （χ2=9.820， P=0.002）， the number of tumors （χ2=57.713， P<0.001）， maximum tumor diameter （χ2=41.862， P<0.001）， portal vein tumor thrombus （χ2=293.909， P<0.001）， extrahepatic metastasis at initial diagnosis （χ2=118.329， P<0.001）， BCLC stage （χ2=465.638， P<0.001）， surgical resection （χ2=78.86， P<0.001）， local treatment （χ2=36.216， P<0.001）， immune checkpoint inhibitor treatment and/or anti-tumor angiogenesis therapy （χ2=7.182， P=0.007）， traditional Chinese medicine decoction treatment （χ2=30.050， P<0.001）， and comprehensive treatment regimens （χ2=13.221， P=0.004）. Progression-free survival （PFS） was recorded for 259 patients （30.5%）， with a median PFS of 10.98 months （95%CI： 8.54 ‍—‍ 13.42）.  Conclusion  HCC patients exhibit epidemiological characteristics in terms of sex， age， place of residence， presence or absence of viral hepatitis， regular antiviral therapy before initial diagnosis， tumor characteristics， treatment modality， and prognosis， with a low early detection rate and a short overall survival time， and therefore， it is urgent to perform early screening， early diagnosis， and early treatment.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    WHO. Data visualization tools for exploring the global cancer burden in 2020[EB/OL].( 2020-01-01)[ 2021-06-16]. https://gco.iarc.fr/today/home. https://gco.iarc.fr/today/home
    [2]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68( 6): 394- 424. DOI: 10.3322/caac.21492.
    [3]
    ZHENG RS, ZHANG SW, SUN KX, et al. Cancer statistics in China, 2016[J]. Chin J Oncol, 2023, 45( 3): 212- 220. DOI: 10.3760/cma.j.cn112152-20220922-00647.

    郑荣寿, 张思维, 孙可欣, 等. 2016年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2023, 45( 3): 212- 220. DOI: 10.3760/cma.j.cn112152-20220922-00647.
    [4]
    VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/s0140-6736(22)01200-4.
    [5]
    MARTEL CD, GEORGES D, BRAY F, et al. Global burden of cancer attributable to infections in 2018: A worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8( 2): e180- e190. DOI: 10.1016/S2214-109X(19)30488-7.
    [6]
    TSILIMIGRAS DI, BAGANTE F, SAHARA K, et al. Prognosis after resection of Barcelona clinic liver cancer(BCLC) stage 0, A, and B hepatocellular carcinoma: A comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019, 26( 11): 3693- 3700. DOI: 10.1245/s10434-019-07580-9.
    [7]
    Specialist Group of Interventional Drugs, Interventionalists Branch of Chinese Medical Doctor Association. Chinese expert consensus on intra-arterial drug and combined drug administration for primary hepatocellular carcinoma[J]. Chin J Intern Med, 2023, 62( 7): 785- 801. DOI: 10.3760/cma.j.cn112138-20230202-00049.

    中国医师协会介入医师分会介入药物专业组. 原发性肝细胞癌经动脉内用药与联合用药中国专家共识[J]. 中华内科杂志, 2023, 62( 7): 785- 801. DOI: 10.3760/cma.j.cn112138-20230202-00049.
    [8]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288- 303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
    [9]
    PETRICK JL, FLORIO AA, ZNAOR A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012[J]. Int J Cancer, 2020, 147( 2): 317- 330. DOI: 10.1002/ijc.32723.
    [10]
    LI QR, CAO MM, LEI L, et al. Burden of liver cancer: From epidemiology to prevention[J]. Chin J Cancer Res, 2022, 34( 6): 554- 566. DOI: 10.21147/j.issn.1000-9604.2022.06.02.
    [11]
    YANG JD, HAINAUT P, GORES GJ, et al. A global view of hepatocellular carcinoma: Trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 10): 589- 604. DOI: 10.1038/s41575-019-0186-y.
    [12]
    CAO MM, DING C, XIA CF, et al. Attributable deaths of liver cancer in China[J]. Chin J Cancer Res, 2021, 33( 4): 480- 489. DOI: 10.21147/j.issn.1000-9604.2021.04.05.
    [13]
    HUANG DQ, TRAN A, YEH ML, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase[J]. Hepatology, 2023, 78( 5): 1558- 1568. DOI: 10.1097/HEP.0000000000000459.
    [14]
    WOJCIECHOWSKA J, KRAJEWSKI W, BOLANOWSKI M, et al. Diabetes and cancer: A review of current knowledge[J]. Exp Clin Endocrinol Diabetes, 2016, 124( 5): 263- 275. DOI: 10.1055/s-0042-100910.
    [15]
    MAK LY, HUI RW, LEE CH, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes[J]. Hepatology, 2023, 77( 2): 606- 618. DOI: 10.1002/hep.32716.
    [16]
    YOU YL, DENG MH, GONG JP. The association between type 2 diabetes mellitus and hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34( 8): 1793- 1796. DOI: 10.3969/j.issn.1001-5256.2018.08.045.

    游宇来, 邓明华, 龚建平. 2型糖尿病与肝细胞癌的关系[J]. 临床肝胆病杂志, 2018, 34( 8): 1793- 1796. DOI: 10.3969/j.issn.1001-5256.2018.08.045.
    [17]
    WANG L, XIAN YT, YANG ZQ, et al. Effect and factor analysis of different treatment strategies on prognosis of advanced hepatocellular carcinoma patients[J/CD]. Chin J Interv Radiol Electron Ed, 2018, 6( 2): 104- 108. DOI: 10.3877/cma.j.issn.2095-5782.2018.02.003.

    王磊, 咸玉涛, 杨正强, 等. 不同治疗方案对晚期肝细胞性肝癌预后的影响及因素分析[J/CD]. 中华介入放射学电子杂志, 2018, 6( 2): 104- 108. DOI: 10.3877/cma.j.issn.2095-5782.2018.02.003.
    [18]
    JUN TW, YEH ML, YANG JD, et al. More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma[J]. Liver Int, 2018, 38( 5): 895- 902. DOI: 10.1111/liv.13613.
    [19]
    HE YJ, ZHANG ZM, HE WM, et al. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1 302 cases[J]. J Clin Hepatol, 2019, 35( 5): 1002- 1007. DOI: 10.3969/j.issn.1001-5256.2019.05.014.

    何雅婧, 张植明, 何伟猛, 等. 1 302例单中心观察性肝细胞癌真实世界队列的流行病学特征与预后[J]. 临床肝胆病杂志, 2019, 35( 5): 1002- 1007. DOI: 10.3969/j.issn.1001-5256.2019.05.014.
    [20]
    LIU QG, SONG T, WANG HH. Re-understanding of surgical resection techniques for liver cancer[J]. Chin J Dig Surg, 2024, 23( 1): 75- 79. DOI: 10.3760/cma.j.cn115610-20231214-00253.

    刘青光, 宋涛, 王欢欢. 肝癌外科手术切除技术的再认识[J]. 中华消化外科杂志, 2024, 23( 1): 75- 79. DOI: 10.3760/cma.j.cn115610-20231214-00253.
    [21]
    SHI K, BI Y, ZENG X, et al. Effects of adjuvant huaier granule therapy on survival rate of patients with hepatocellular carcinoma[J]. Front Pharmacol, 2023, 14: 1163304. DOI: 10.3389/fphar.2023.1163304.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (185) PDF downloads(33) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return